New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

While real-time data on how Indians are responding to these drugs is still emerging, experts say that sustained weight loss ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Glucagon-like peptide-1 (GLP-1) injections such as Wegovy (semaglutide) and Zepbound (tirzepatide) are the most effective weight-loss medications available today. Oral GLP-1 pills, such as ...

WEIGHT loss, warding off dementia, ‘curing’ diabetes and now… anti-ageing powers? Is there anything the so-called fat jabs can’t do? While a medicine that reverses the clock would be a ...

Oral semaglutide was associated with more pronounced cardiovascular benefits among patients with higher baseline HbA1c in ...

Semaglutide was associated with improved maximum walking distance across type 2 diabetes subgroups among patients with ...

Diabetics are more likely to develop Alzheimer’s than the general public. Could a popular diabetes and weight-loss drug also ...

New study details gaps between actual and recommended use of statins and other lipid-lowering drugs—and estimates public ...